Literature DB >> 12899531

Induction of apoptosis by vitamin D metabolites and analogs in a glioma cell line.

Josef Elias1, Brigitte Marian, Christa Edling, Bodo Lachmann, Christian R Noe, Schulte-Hermann Rolf, Inge Schuster.   

Abstract

Gliomas are the most common malignant tumors in brain. Recent studies demonstrate the capacity of 1alpha,25(OH)2D3 to specifically induce cell death (apoptosis) in model glioma cell lines and in primary cultures from tumor tissue, but not in primary astrocytes. In spite of this promising activity, a broad therapeutic application of vitamin D metabolites and analogs is still restricted because of their poor bioavailability and their hypercalcemic actions. Compared to 1alpha,25(OH)2D3, its natural 3alpha-epimer exhibits far higher metabolic stability and a reduced calcemic effect. Focusing on a possible therapeutic advantage of the 3alpha-conformation, we have examined the apoptotic potential of a representative set of vitamin D analogs, each of them in the 3alpha- and 3beta-conformation, and of natural vitamin D metabolites in the rat C6 glioma cell line. Exposure of these cells to the synthetic analogs resulted in all cases in a pronounced reduction of cell density (tested by incorporation of neutral red) and induction of apoptosis, monitored by staining nuclei with Hoechst 33258 dye and by following DNA fragmentation by capillary electrophoresis. The 3alpha-epimers showed equivalent or even higher activity on C6 cells than their respective 3beta forms. For their potent effects on growth and apoptosis of tumor cells and their high metabolic stability combined with a low calcemic potential, we speculate that these 3a-epimers could provide advantages for a prospective treatment of glioma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899531     DOI: 10.1007/978-3-642-55580-0_22

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  7 in total

1.  Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma.

Authors:  Victoria Zigmont; Amy Garrett; Jin Peng; Michal Seweryn; Grzegorz A Rempala; Randall Harris; Christopher Holloman; Thomas E Gundersen; Anders Ahlbom; Maria Feychting; Tom Borge Johannesen; Tom Kristian Grimsrud; Judith Schwartzbaum
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

2.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

Review 3.  Vitamin D deficiency in chronic liver disease.

Authors:  Paula Iruzubieta; Álvaro Terán; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2014-12-27

Review 4.  Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents.

Authors:  Athanassios P Kyritsis; Melissa L Bondy; Victor A Levin
Journal:  Nutr Cancer       Date:  2011       Impact factor: 2.900

5.  Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme.

Authors:  Débora G Salomón; María E Fermento; Norberto A Gandini; María J Ferronato; Julián Arévalo; Jorge Blasco; Nancy C Andrés; Jean C Zenklusen; Alejandro C Curino; María M Facchinetti
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

Review 6.  Not enough vitamin D: health consequences for Canadians.

Authors:  Gerry Schwalfenberg
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

7.  An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome.

Authors:  Gabriella M Anic; Reid C Thompson; L Burton Nabors; L Burton Nabors; Jeffrey J Olson; James E Browning; Melissa H Madden; F Reed Murtagh; F Reed Murtagh; Peter A Forsyth; Kathleen M Egan
Journal:  Cancer Causes Control       Date:  2012-06-28       Impact factor: 2.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.